KPC Pharmaceuticals,Inc. Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	502.71	1,235	2,266	1,500	1,658	1,574
Trading Asset Securities	1,122	1,109	471.28	603.8	319.4	160.5
Cash & Short-Term Investments	1,624	2,344	2,737	2,103	1,978	1,735
Cash Growth	-40.08%	-14.37%	30.13%	6.35%	14.01%	-4.68%
Accounts Receivable	3,504	3,527	3,855	3,225	2,625	2,011
Other Receivables	151.46	188.15	123.73	797.75	95.1	169.09
Receivables	3,655	3,716	3,979	4,022	2,720	2,180
Inventory	1,513	1,383	1,540	1,772	1,681	1,884
Other Current Assets	331.81	281.6	299.64	250.14	388.21	381.96
Total Current Assets	7,124	7,724	8,555	8,148	6,766	6,180
Property, Plant & Equipment	1,239	1,252	1,286	1,307	1,291	1,361
Long-Term Investments	426.36	377.22	305.46	319.61	320.61	278.24
Goodwill	1,499	1,499	1,503	1,503	91.73	91.73
Other Intangible Assets	362.25	373.31	412.22	441.97	355.98	408.88
Long-Term Deferred Tax Assets	222.06	216.31	258.28	269.12	245.6	233.83
Long-Term Deferred Charges	283.33	270.03	237.84	237	199.07	274.49
Other Long-Term Assets	59.96	62.01	53.12	69.83	161.17	64.98
Total Assets	11,215	11,774	12,611	12,295	9,432	8,893
Accounts Payable	783.55	876.24	1,056	936.78	977.12	1,239
Accrued Expenses	251.52	1,522	1,831	1,597	1,262	1,117
Short-Term Debt	751.98	813.37	658.04	725.49	912.76	641.75
Current Portion of Long-Term Debt	122.39	109.19	61.05	1	99.5	0.2
Current Portion of Leases	-	25.98	19.28	22.46	22.57	36.07
Current Income Taxes Payable	56.33	51.48	158.94	149.75	78.76	93.28
Current Unearned Revenue	50.38	51.46	83.32	102.63	186.37	74.09
Other Current Liabilities	1,396	375.56	1,624	329.7	350.01	284.76
Total Current Liabilities	3,412	3,826	5,491	3,865	3,889	3,485
Long-Term Debt	693.47	683.24	46.05	107.56	60	99.5
Long-Term Leases	47.69	53.42	48.59	44.24	44.77	50.47
Long-Term Unearned Revenue	239.23	243.24	229.92	224.09	207.58	245.34
Long-Term Deferred Tax Liabilities	20.57	21.64	21.65	24.28	10.64	15.42
Other Long-Term Liabilities	4.97	4.93	28.03	75.97	77.58	56.67
Total Liabilities	4,418	4,832	5,865	4,341	4,289	3,953
Common Stock	756.98	756.98	756.98	757.99	758.26	758.26
Additional Paid-In Capital	522.1	519.66	520.62	2,327	1,161	1,169
Retained Earnings	3,973	4,114	3,981	3,490	3,071	2,894
Treasury Stock	-	-	-	-10.42	-13.15	-26.3
Comprehensive Income & Other	-30.04	-28.67	-5.29	-1.62	6.3	-11.5
Total Common Equity	5,222	5,362	5,254	6,562	4,983	4,783
Minority Interest	1,576	1,579	1,493	1,392	159.5	156.98
Shareholders' Equity	6,798	6,941	6,746	7,954	5,143	4,940
Total Liabilities & Equity	11,215	11,774	12,611	12,295	9,432	8,893
Total Debt	1,616	1,685	833.02	900.74	1,140	828
Net Cash (Debt)	8.7	658.37	1,904	1,203	838.19	906.76
Net Cash Growth	-99.16%	-65.42%	58.33%	43.47%	-7.56%	-9.49%
Net Cash Per Share	0.01	0.87	2.53	1.58	1.12	1.20
Filing Date Shares Outstanding	746.23	756.98	756.98	757.11	758.13	758.26
Total Common Shares Outstanding	746.23	756.98	756.98	757.99	758.26	758.26
Working Capital	3,712	3,898	3,064	4,283	2,878	2,695
Book Value Per Share	7.00	7.08	6.94	8.66	6.57	6.31
Tangible Book Value	3,360	3,490	3,338	4,617	4,535	4,283
Tangible Book Value Per Share	4.50	4.61	4.41	6.09	5.98	5.65
Buildings	-	1,338	1,325	1,262	1,137	1,136
Machinery	-	1,059	1,058	1,011	988.66	980.07
Construction In Progress	-	100.4	76.46	100.51	64.65	43.51

Source: S&P Global Market Intelligence. Standard template. Financial Sources.